Last reviewed · How we verify
SCT200
At a glance
| Generic name | SCT200 |
|---|---|
| Also known as | Anti-EGFR monoclonal antibody |
| Sponsor | Sinocelltech Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PHASE1)
- SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma (PHASE2)
- Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma (PHASE2)
- Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC (PHASE1)
- Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma (PHASE1, PHASE2)
- Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer (PHASE1)
- SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma (PHASE2)
- Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCT200 CI brief — competitive landscape report
- SCT200 updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI